Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • Classified ads
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
SynopsisH

Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss

Eric Wooltorton
CMAJ March 15, 2005 172 (6) 746; DOI: https://doi.org/10.1503/cmaj.050158
Eric Wooltorton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

Reason for posting: Medroxyprogesterone acetate is an injectable agent widely used for contraception and the treatment of endometriosis. However, a warning was recently issued that patients taking this drug may experience a significant loss of bone mineral density.1

The drug: Medroxyprogesterone acetate is injected intramuscularly in a standard dose (150 mg) once every 3 months. It confers its reversible contraceptive effect by inhibiting gonadotropin secretion, preventing follicle maturation and ovulation, and causing endometrial thinning. Disrupted menses (bleeding, amenorrhea or both), fluid retention, weight changes, dizziness, headache, weakness and fatigue are frequently experienced by women taking the drug. Other rare but serious adverse effects include mood changes, thromboembolic diseases, ocular disorders (including vision loss, proptosis, diplopia or migraine) and reduced glucose tolerance. About 3 in 1000 women taking the drug will experience an accidental pregnancy in the first year of continuous use. It is contraindicated in pregnant women, women who have undiagnosed vaginal bleeding, malignant breast disease, active thrombophlebitis, past thromboembolic disorders or cerebral vascular disease, and in women with significant liver disease.

Medroxyprogesterone acetate decreases serum estrogen levels, which can lead to bone mineral density loss. In an unpublished study involving women above the age of 18 who used the drug for up to 5 years, bone mineral density in the spine and hip was reduced by 5% to 6% below baseline.2 In contrast, women in the control group, who were not using hormonal contraception, had no significant change in bone mineral density. Loss of density was greatest in the first 2 years of use. Two years after stopping the drug, bone mineral density was only partially recovered. Preliminary results from an ongoing open-label self-selected nonrandomized group of adolescent women aged 12–18 years showed a similar decrease in bone mineral density of 4%–6.9% after 4.6 years of study.2 This decline was not seen in a group of unmatched adolescents not receiving the drug. It is unknown whether use of medroxyprogesterone acetate will lead to osteoporotic fractures later in life.

What to do: This drug, which is widely taken by patients for whom compliance is an issue (e.g., adolescents and young adults), may cause a loss of bone density that may not be fully reversible in a group that is least able to afford such a loss. A patient's risk factors for osteoporosis (a family history of osteoporosis; long-term use of glucocorticoids, heparin or anticonvulsant therapy; malabsorption states; hyperparathyroidism; hyperthyroidism; smoking; low dietary calcium intake; excessive caffeine or alcohol intake; weight 57 kg; anorexia or bulemia)2,3 should be part of the risk–benefit analysis of prescribing the drug. Only if other methods of birth control are inappropriate should the drug be used as a contraceptive for the long term (> 2 years). Women who take the drug for more than 2 years should have their bone mineral density monitored. When interpreting bone mineral density test results in adolescents, the patient's age and degree of skeletal maturation should be taken into account. Studies are lacking on how best to prevent and treat medroxyprogesterone acetate-associated bone mineral density loss; however, it may be wise to routinely recommend regular weight-bearing exercise, smoking cessation, and calcium and vitamin D supplementation to women prescribed the drug.

References

  1. 1.↵
    Health Canada endorsed important safety information on Depo-Provera (medroxyprogesterone acetate) [letter]. Nov. 22, 2004. Available: www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/depo-provera_hpc_e.html (accessed 2005 Feb 8).
  2. 2.↵
    Depo-Provera (medroxyprogesterone acetate injectable suspension) revised product monograph, Pfizer. Available: www.fda.gov/medwatch/SAFETY/2004/safety04.htm#Depo [click on: November, 2004 - Label - Pfizer] (accessed 2005 Feb 8).
  3. 3.↵
    Brown JP, Josse RG, for the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl):S1-34.
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (6)
CMAJ
Vol. 172, Issue 6
15 Mar 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss
Eric Wooltorton
CMAJ Mar 2005, 172 (6) 746; DOI: 10.1503/cmaj.050158

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss
Eric Wooltorton
CMAJ Mar 2005, 172 (6) 746; DOI: 10.1503/cmaj.050158
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • A newborn requiring selective bronchial intubation
  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
  • The changing ecology of avian flu
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Osteoporosis
    • Health technology

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

Powered by HighWire